Showing 161 - 180 results of 111,653 for search '(( significant time based ) OR ( significant ((main decrease) OR (a decrease)) ))', query time: 1.26s Refine Results
  1. 161
  2. 162
  3. 163
  4. 164
  5. 165
  6. 166

    Image_1_The significance of time interval between perioperative SOX/XELOX chemotherapy and clinical decision model in gastric cancer.pdf by Jun-Bing Chen (14296940)

    Published 2022
    “…Analogously, there was a significant decrease for dichotomous TTS (within vs over 5 weeks) in OS (P = .03) and progression free survival (PFS) (P = .01) but not for dichotomous TAC (within vs over 6 weeks) in OS and PFS (P = .40). …”
  7. 167

    Image_2_The significance of time interval between perioperative SOX/XELOX chemotherapy and clinical decision model in gastric cancer.pdf by Jun-Bing Chen (14296940)

    Published 2022
    “…Analogously, there was a significant decrease for dichotomous TTS (within vs over 5 weeks) in OS (P = .03) and progression free survival (PFS) (P = .01) but not for dichotomous TAC (within vs over 6 weeks) in OS and PFS (P = .40). …”
  8. 168

    Table_2_The significance of time interval between perioperative SOX/XELOX chemotherapy and clinical decision model in gastric cancer.docx by Jun-Bing Chen (14296940)

    Published 2022
    “…Analogously, there was a significant decrease for dichotomous TTS (within vs over 5 weeks) in OS (P = .03) and progression free survival (PFS) (P = .01) but not for dichotomous TAC (within vs over 6 weeks) in OS and PFS (P = .40). …”
  9. 169

    Table_3_The significance of time interval between perioperative SOX/XELOX chemotherapy and clinical decision model in gastric cancer.docx by Jun-Bing Chen (14296940)

    Published 2022
    “…Analogously, there was a significant decrease for dichotomous TTS (within vs over 5 weeks) in OS (P = .03) and progression free survival (PFS) (P = .01) but not for dichotomous TAC (within vs over 6 weeks) in OS and PFS (P = .40). …”
  10. 170

    Table_1_The significance of time interval between perioperative SOX/XELOX chemotherapy and clinical decision model in gastric cancer.docx by Jun-Bing Chen (14296940)

    Published 2022
    “…Analogously, there was a significant decrease for dichotomous TTS (within vs over 5 weeks) in OS (P = .03) and progression free survival (PFS) (P = .01) but not for dichotomous TAC (within vs over 6 weeks) in OS and PFS (P = .40). …”
  11. 171
  12. 172
  13. 173
  14. 174
  15. 175
  16. 176
  17. 177
  18. 178
  19. 179
  20. 180